Rachel Dorsett Catevenis, PA-C

Rachel Catevenis practices at Genesis Healthcare Partners in San Diego, California.

Rachel Catevenis' NPI, 1225583735, was assigned on August 25, 2016.

Rachel Catevenis' primary practice is Genesis Healthcare Partners, at 3366 5th Ave, San Diego, CA 92103 in San Diego County. The practice phone is (760) 436-4558.

Rachel Catevenis' primary practice is Genesis Healthcare Partners in San Diego, California. Rachel Catevenis is also affiliated with Santa Barbara Cottage Hospital. The medical group on file is Unio Specialty Care, Urology, Encinitas (formerly Genesis Healthcare Partners). Dmand AI also links Rachel Catevenis to 2 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Rachel Catevenis practices, 5 sites in all. Vendor and product names are available with a free account.

Physician assistant is Rachel Catevenis' primary specialty in the NPI Registry, under taxonomy code 363A00000X. Rachel Catevenis has a license on file in California.

Dmand AI lists chronic indigestion, drug use disorders, gastroenteritis, hemorrhoids, upper respiratory infection (URI) and yeast infection among the conditions Rachel Catevenis treats.

CMS data shows 717 Medicare services from Rachel Catevenis across 5 procedure codes in 2024, for 523 Medicare patients. Medicare paid $68,599 for them. Every service was in an office.

CMS counts 523 Medicare patients who saw Rachel Catevenis in 2024. The largest group is 65 to 74, with 224 patients. 75% of them have high cholesterol, and 64% have high blood pressure. 15% are also on Medicaid. Their average risk score is 1.11, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Rachel Catevenis' median patient age at 62, with 61% women.

In 2024, Rachel Catevenis wrote 2,230 Medicare Part D claims for 1,289 patients. 87% of them were for generic drugs. CMS names the drug for 2,049 of them, across 24 drugs with 11 or more claims each, at $862,172 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Rachel Catevenis for performance year 2024, reported as part of a group. Rachel Catevenis accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Rachel Catevenis as offering telehealth.

CMS Open Payments shows 99 general payments to Rachel Catevenis from 17 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 96% of the total. Janssen Pharmaceuticals, Inc paid the most, $645.